Hasil Pencarian  ::  Simpan CSV :: Kembali

"Kemoterapi merupakan salah satu modalitas terapi kanker payudara. Kombinasi dari 5-fluorourasil, doksorubisin, dan siklofosfamid (FAC) adalah protokol kemoterapi yang paling banyak digunakan. Penelitian ini bertujuan untuk mengidentifikasi masalah terkait obat pada pasien kanker payudara yang menjalani kemoterapi FAC di Rumah Sakit Kanker Dharmais dalam periode Juli-Desember 2019. Penelitian dilakukan menggunakan metode observasional deskriptif dengan desain penelitian potong lintang (cross-sectional) menggunakan data restropektif. Masalah terkait obat yang diidentifikasi pada penelitian ini, meliputi dosis dan interaksi obat. Hasil penelitian menunjukkan insiden kanker payudara tertinggi pada kelompok umur 44-54 tahun (43,70%) dan penggunaan obat penunjang tertinggi terdapat pada ondansetron (27,17%). Masalah terkait obat dengan dosis yang tidak sesuai sebesar 9,24%, di mana 7,56% dosis terlalu rendah dan 1,68% dosis terlalu tinggi, dan interaksi obat sebesar 9,24%, dimana 25% kategori mayor, 69,44% kategori moderat, dan 5,56% kategori minor. Penatatalaksana kemoterapi FAC pada pasien kanker payudara berpotensi menyebabkan masalah terkaitobat. Oleh karena itu, perlu pemantauan terapi obat pada pasien agar masalah terkait obat dapat diminimalisasi sehingga keberhasilan terapi dapat tercapai.

---

Chemotherapy is one of the modalities of breast cancer therapy. The combination of 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) is the most widely use chemotherapy protocol. This study aims to identify drug-related problems in breast cancer patients undergoing FAC chemotherapy at Dharmais Cancer Hospital in the period July-December 2019. The study was conducted using descriptive observational methods with cross-sectional research designs using restropective data. Drug-related problems identified in this study included dosage and drug interactions.

The results showed the highest breast cancer incident showed in the age group 44-54 years old (43.70%) and the highest use of supportive therapy was found in ondansetron (27.17%). Percentage of inappropriate doses was 9.24% with 7.56% doses too low and 1.68% doses too high, and drug interactions by 9.24%, where 25% the major category, 69.44% the moderate category, and 5.56% the minor category. Management of FAC chemotherapy in breast cancer patients has the potential to cause drug-related problems. Therefore, it is necessary to monitor drug therapy in patients so that drug-related problems can be minimized andtherapeutic success can be achieved."

"Breast and prostate cancers are both hormone-dependent, at least in some stages of their progression. Hormonal manipulation represents an important therapeutic approach. Although most of breast and prostate cancers initially respond to hormone therapy, most tumors reinitiate to growth. Finally, hormone-resistant and metastatic breast and prostate cancers may develop. Thus, the challenge is the dissection of mechanisms by which steroid receptor signaling pathways continue to influence cell growth and invasiveness. Compelling evidence indicates that steroid hormones elicit non-genomic responses in extra-nuclear compartment of target cells. In this cellular location, steroid-coupled receptors rapidly recruit signaling effectors or scaffold proteins and activate multiple pathways leading to proliferation, survival, migration and invasiveness. The immediate challenge is the dissection of key events regulating the steroid response of target tissues to prevent progression and improve treatment of breast and prostate cancers."